A Skin-Longevity Prescription Combines Actives With Unequal Evidence.

One range, three different evidence histories

Agency Skin’s August 2026 launch brings several prescription ingredients under a “skin longevity” label. Its clinician-directed range may use tretinoin and estriol in a night formulation and sirolimus, also called rapamycin, in a separate product. The company’s descriptions say a licensed clinician selects and adjusts each patient’s formulation. The presence of these ingredients in one range does not make their evidence for photoaging equivalent. ^{[1, 2]}

Tretinoin has an established history in topical photoaging research. A U.S. drug label for a 0.05% tretinoin cream supports its use as an adjunct to a wider skincare and sun-avoidance program for fine facial wrinkles, mottled hyperpigmentation and tactile roughness; it also says the medicine does not eliminate wrinkles or reverse photoaging. That label is for a named finished product, not for Agency Skin’s compounded mixtures. ^[3]

Early research is not a finished-compound result

An older estriol study enrolled 59 women across estradiol and estriol arms and reported changes in several skin-aging measures after six months. Its size, date and products limit how far the result can be carried into a new combination. A small exploratory randomized study of topical rapamycin reported changes in aging-related skin markers, but substantial attrition and limited samples leave important questions open. Neither study tests Agency Skin’s finished prescriptions. ^{[4, 5]}

Sirolimus has a U.S.-approved topical gel for facial angiofibromas associated with tuberous sclerosis. That approval concerns a different condition and product; it is not an FDA approval for treating skin aging with the new compound. Agency Skin itself describes Cell Repair Rx as a compounded prescription and supplies product-specific safety information. ^{[2, 6]}

What a reader can take from the launch

This is a service and product-design move: selecting ingredients, strengths and follow-up within a clinical consultation. It is not a single clinical trial showing that the entire range slows aging. For each finished mixture, the useful questions remain what was dispensed, who was studied, how tolerability was assessed, and what outcome was measured. No involvement by N1 Life in Agency Skin’s products is asserted here.

Sources

1. Agency Skin. Science-First Approach to Skin Longevity.
2. Agency Skin. Cell Repair Rx, product and safety information.
3. DailyMed. Tretinoin Cream USP (Emollient) 0.05%, prescribing information.
4. Schmidt JB, et al. Treatment of skin aging with topical estrogens. Int J Dermatol. 1996.
5. Chung CL, et al. Topical rapamycin reduces markers of senescence and aging in human skin. GeroScience. 2019.
6. U.S. FDA. HYFTOR (sirolimus topical gel) prescribing information.